ND Pharma Research Advance on Filovirus Field

Research on filovirus (Ébola, Marburg, etc.) infection therapeutics is being held by ND Pharma & Biotech Leading Research Team in partnership with two Top US Universities and respective Medical Centers. The research, fairly advanced is actually centered on the application of a biotech-engineered serum/product that once melted with Saline Serum and a portion of patient´s blood is showing promising results not only on the inertization of virus but microfragmentation of virus capsides reaching a complete destruction of viruses´ structure, antibody generation triggering and organ/tissue respect with a minimum or none side effects or sequelae. The product may be applied by direct infusion or alternatively (to advanced infection staged) applied by contact with blood throughout a simple device as dialysis machine under medical supervision. The proposed dosis of 50 cc (unit) if approved, will be cheap, cost-effective and will permit to fight safely and efficiently the infection and epidemics within the origin countries and locations as well as in the ocasional transmission and arrival in developed countries, as the US and/or EU.
As product is not being yet approved for commercialization, "compassive use/therapy" units of Serum (ND 33456·FiloSerum) were offerer for free to different institutions, Medical Centers and Hospitals attending infected patients in different countries.